Search results
Results from the WOW.Com Content Network
Large, high quality research has found small differences in the brain between ADHD and non-ADHD patients. [1] [15] Jonathan Leo and David Cohen, critics who reject the characterization of ADHD as a disorder, contended in 2003 and 2004 that the controls for stimulant medication usage were inadequate in some lobar volumetric studies, which makes it impossible to determine whether ADHD itself or ...
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Methylphenidate, sold under the brand names Ritalin (/ ˈ r ɪ t ə l ɪ n / RIT-ə-lin) and Concerta (/ k ə n ˈ s ɜːr t ə / kən-SUR-tə) [citation needed] among others, is a central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy.
The Ritalin class-action lawsuits were a series of federal lawsuits in 2000, filed in five separate US states. [1] All five lawsuits were dismissed by the end of 2002. The lawsuits alleged that the makers of methylphenidate (brand name Ritalin) and the American Psychiatric Association had conspired to invent and promote the disorder ADHD to create a highly profitable market for the drug.
For instance, in 2011, eighth and 11th graders were expected to use computers to complete the National Assessment of Educational Progress's writing test, and the same requirement went into effect ...
Ritalin (methylphenidate) – a stimulant used to treat ADHD; ReVia – an opioid antagonist primarily used in the management of alcohol dependence, opioid dependence or other impulse control/addictive behaviors such as habitual self-mutilation; Rexulti (brexpiprazole) – atypical antipsychotic used to treat mood and psychotic disorders
Children with gender dysphoria deserve clearer answers." U.S. v. Skrmetti centers on a Tennessee law that bans gender-transition treatments for minors in the state.
Serdexmethylphenidate is a prodrug of dexmethylphenidate created by the pharmaceutical company KemPharm (now Zevra Therapeutics). The compound was first approved by the FDA as one of the active ingredients in Azstarys for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults in March 2021.